Header Logo

The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-? antagonist therapies.

Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-? antagonist therapies. Clin Exp Rheumatol. 2013 Mar-Apr; 31(2):189-94.

View in: PubMed